SCHEMBL918752

SCHEMBL918752

CC(C)(C)NCCS(=O)(=O)O

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.36
BLM P54132 2/20 0.36
PTGS1 P23219 1/20 0.36
PDE4A P27815 1/20 0.36
SLC6A6 P31641 1/20 0.36
CYP2C19 P33261 1/20 0.36
KDM4E B2RXH2 1/20 0.34
CASP1 P29466 1/20 0.34
CASP7 P55210 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HIF1A Q16665 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
APP P05067 1/20 0.33
CYP2D6 P10635 1/20 0.33
POLB P06746 1/20 0.32
EPHX2 P34913 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4404059 0.98 LMNA (0.35) LMNABLMPTGS1PDE4ASLC6A6
SCHEMBL353687 0.86 APP (0.41) LMNABLMPTGS1PDE4ASLC6A6
SCHEMBL353864 0.86 APP (0.41) LMNABLMPTGS1PDE4ASLC6A6
SCHEMBL4412454 0.84 APP (0.39) LMNABLMPTGS1PDE4ASLC6A6
SCHEMBL22800827 0.84 EPHX2 (0.41) LMNABLMPTGS1PDE4ASLC6A6
SCHEMBL439388 0.83 PTGS1 (0.35) LMNABLMPTGS1PDE4ASLC6A6
SCHEMBL4736677 0.79 PTGS1 (0.32) LMNABLMPTGS1PDE4ASLC6A6
SCHEMBL11140851 0.79 PTGS1 (0.32) LMNABLMPTGS1PDE4ASLC6A6
SCHEMBL29272709 0.79
SCHEMBL22800803 0.79 KDM4E (0.38) PTGS1PDE4AKDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240218011-A1 GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF FIREFLY BIO, INC. 2024-07-04 US disclosed
EP-4107198-B1 POLYISOCYANATE PREPARATIONS COVESTRO DEUTSCHLAND AG (DE) 2024-03-13 EP disclosed
US-20240067640-A1 PHENYL MALEIMIDE LINKER AGENTS FIREFLY BIO, INC. 2024-02-29 US disclosed
US-20240067640-A1 PHENYL MALEIMIDE LINKER AGENTS FIREFLY BIO, INC. 2024-02-29 US disclosed
EP-3560975-B2 IONICALLY HYDROPHILIZED POLYISOCYANATES AND ANTIOXIDANTS COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) 2023-12-06 EP disclosed
EP-3724251-B2 IONICALLY HYDROPHILIZED POLYISOCYANATES, WATER CONTENT COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) 2023-11-22 EP disclosed
US-20230321048-A1 ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS MERSANA THERAPEUTICS, INC. 2023-10-12 US disclosed
US-11701369-B2 Polymeric bile acid derivatives inhibit Hepatitis B and D virus and NTCP transport HUAHUI HEALTH LTD. (CN) 2023-07-18 US disclosed
US-20230172910-A1 ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS MERSANA THERAPEUTICS, INC. 2023-06-08 US disclosed
EP-3851472-B1 IONICALLY HYDROPHILIZED POLYISOCYANATES, WATER CONTENT COVESTRO INTELLECTUAL PROPERTY GMBH & CO KG (DE) 2023-06-07 EP disclosed
US-7253306-B2 Pharmaceutical drug candidates and methods for preparation thereof NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2007-08-07 US disclosed
US-20070010573-A1 Methods and compositions for treating amyloid-related diseases BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) 2007-01-11 US disclosed
US-20070010573-A1 Methods and compositions for treating amyloid-related diseases BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) 2007-01-11 US disclosed
US-20070010573-A1 Methods and compositions for treating amyloid-related diseases BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) 2007-01-11 US disclosed
EP-1646659-A2 IMPROVED PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF Neurochem (International) Limited (CH) 2006-04-19 EP disclosed
EP-1644325-A2 METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES Neurochem (International) Limited (CH) 2006-04-12 EP disclosed
US-20050143462-A1 Pharmaceutical drug candidates and methods for preparation thereof NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2005-06-30 US disclosed
US-20050096385-A1 Methods and compositions for treating amyloid-related diseases BHI LIMITED PARTNERSHIP (CA) 2005-05-05 US disclosed
WO-2004113391-A2 IMPROVED PHARMACEUTICAL DRUG CANDIDATES AND METHODS FOR PREPARATION THEREOF NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2004-12-29 WO disclosed
WO-2004113275-A2 METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES NEUROCHEM (INTERNATIONAL) LIMITED (CH) 2004-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240218011-A1 GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF NR3C1, NR3C2, MC2R LMNA 4639/4885BLM 1775/4885PTGS1 605/4885
US-11701369-B2 Polymeric bile acid derivatives inhibit Hepatitis B and D virus and NTCP transport SLC10A1, SLC10A2, ABCB11 LMNA 4691/4885BLM 2475/4885PTGS1 3330/4885
US-20050143462-A1 Pharmaceutical drug candidates and methods for preparation thereof MPST, TTR, STS LMNA 1815/4885BLM 2999/4885PTGS1 400/4885
US-20230321048-A1 ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS STING1, CGAS, IFNAR1 LMNA 4461/4885BLM 205/4885PTGS1 3396/4885
US-20230172910-A1 ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS STING1, CGAS, IFNAR1 LMNA 4461/4885BLM 205/4885PTGS1 3396/4885
US-20240067640-A1 PHENYL MALEIMIDE LINKER AGENTS TPX2, H1-4, MAPT LMNA 233/4885BLM 1932/4885PTGS1 4763/4885
US-20050096385-A1 Methods and compositions for treating amyloid-related diseases APP, PSEN1, PSEN2 LMNA 71/4885BLM 459/4885PTGS1 1584/4885
US-20070010573-A1 Methods and compositions for treating amyloid-related diseases APP, PSEN1, PSEN2 LMNA 71/4885BLM 459/4885PTGS1 1584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.